PHILADELPHIA — The University of Pennsylvania’s Institute for Translational Medicine and Therapeutics’ 10th Annual International Symposium will cover translational science in academic medical centers and biotech along with the impact of innovative technologies such as super-resolution imaging, optogenetics, and the new gene editing tool CRISPR-Cas9. Speakers will include experts in precision medicine, pharmacogenetics, RNA biology, DNA nanotech, and neurodegenerative diseases.
Robert Califf, MD, the recently nominated FDA commissioner, will speak about the role of the FDA in translating fundamental discoveries into therapies.
Date: Monday and Tuesday, October 12-13, 2015, starting at 8:30 am.
Location: Smilow Center for Translational Research, Rubenstein Auditorium and Lobby, 3400 Civic Center Blvd, Philadelphia, PA 19104
Additional details:
The symposium will feature presentations in six major areas:
- Translational Science
- The Evolving Search for Drug Targets
- Big Data and the Phenome
- Systems Approaches to Pharmacology
- Parsing Variability in Pathogenesis of Disease
- Emerging Therapeutic Paradigms in Cancer
Garret A. FitzGerald, MD, FRS, director of ITMAT, will host the event. Speakers and talks include:
- Ronald M. Evans, PhD, professor, The Salk Institute for Biological Studies, investigator, Howard Hughes Medical Institute, March of Dimes Chair in Molecular and Developmental Biology
Nuclear receptors and the Hunger Games
- Jason H. Moore, PhD, professor and director, Penn Institute for Biomedical Informatics, University of Pennsylvania
Combinatorial pharmacogenetics
- Stefanie Dimmeler, PhD, Institute of Cardiovascular Regeneration, Goethe University Frankfurt
Non-coding RNAs: Therapeutic targets in cardiovascular diseases
- Karl Deisseroth MD, PhD, D. H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences, Stanford University
Optical deconstruction of fully-assembled biological systems
- Virginia M.-Y. Lee, PhD, professor of Pathology and Laboratory Medicine, director, Center for Neurodegenerative Disease Research, Perelman School of Medicine of the University of Pennsylvania
Transmission of misfolded proteins in neurodegenerative disorders: A common mechanism of disease progression
For additional details and presentation times, visit the 2015 Agenda
Registration is required for attendance and for participation via web:
Funding for this conference was made possible in part from the National Center for Advancing Translational Sciences.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, excellence in patient care, and community service. The organization consists of the University of Pennsylvania Health System and Penn’s Raymond and Ruth Perelman School of Medicine, founded in 1765 as the nation’s first medical school.
The Perelman School of Medicine is consistently among the nation's top recipients of funding from the National Institutes of Health, with $550 million awarded in the 2022 fiscal year. Home to a proud history of “firsts” in medicine, Penn Medicine teams have pioneered discoveries and innovations that have shaped modern medicine, including recent breakthroughs such as CAR T cell therapy for cancer and the mRNA technology used in COVID-19 vaccines.
The University of Pennsylvania Health System’s patient care facilities stretch from the Susquehanna River in Pennsylvania to the New Jersey shore. These include the Hospital of the University of Pennsylvania, Penn Presbyterian Medical Center, Chester County Hospital, Lancaster General Health, Penn Medicine Princeton Health, and Pennsylvania Hospital—the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is an $11.1 billion enterprise powered by more than 49,000 talented faculty and staff.